-
Recent Posts:
Recent Comments:
Latest PLoG Posts
- Repost: The Pay-for-Delay Tactic in Work In Progress
- How to Find a Fossil in Work In Progress
- Book Review: The Recession Hurt Many People, Now Austerity is Hurting More in Work In Progress
- PLOS ONE welcomes RIAT (Restoring Invisible and Abandoned Trials) Initiative in Work In Progress
- Living science: the importance of science experiences in Brazil in Work In Progress
You may also be interested in:
Click to go to this PLOS Medicine collection
Blog Archives
What’s Next for Hepatitis C
By Jessica Wapner
Posted: June 9, 2011
Posted: June 9, 2011
Category: Drug Development, Hepatitis C
|
Tagged boceprevir, Charles Rice, HCV, HCV genotypes, hepatitis C, injection drug use, Merck, protease inhibition, Ralf Bartenschlager, telaprevir, Vertex
|
11 Comments
Jessica Wapner is a freelance writer focused mainly on biomedical issues. Her work is published in Scientific American, The New York Times, Slate, Science, Nature Medicine, and elsewhere. Her first book, The Philadelphia Chromosome is forthcoming from The Experiment in May 2013.